AbbVie Inc.

Abbvie Romania Recognized as the Best Place To Work in Romania for 2019

Retrieved on: 
Thursday, December 12, 2019
Biotechnology, Health, Professional services, Pharmaceutical, Human resources, Geography of Europe, Europe, Countries, Workplace, AbbVie Inc., Romania

Abbvie Romania was awarded the best place to work in Romania for 2019 according to the prestigious annual Best Workplaces program.

Key Points: 
  • Abbvie Romania was awarded the best place to work in Romania for 2019 according to the prestigious annual Best Workplaces program.
  • Abbvie Romania, part of the global biopharmaceutical company, received outstanding scores across several aspects of their workplace such as teamwork, relationships, leadership and personal growth of the employees resulting in its recognition as the employer of choice in Romania for 2019.
  • It just goes to show that being intentional about culture delivers bottom-line results said Daniela Mardare, Program Manager for Romania.
  • The Best Places To Work Program certifies and recognizes leading workplaces in many countries including leading programs in Africa, Europe, Middle East and Asia.

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue

Retrieved on: 
Wednesday, December 11, 2019
Financial markets, Stock market, Finance, Financial economics, Corporate finance, AbbVie Inc., Security, Stock exchange, Stock, New York Stock Exchange

AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.

Key Points: 
  • AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.
  • The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.
  • Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.
  • Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics

Retrieved on: 
Monday, December 9, 2019
Florida Atlantic University, La Jolla, San Diego, Scripps Research, Companies, AbbVie Inc., Scripps, Illinois, Economy of the United States

Scripps and AbbVie will also work together in parallel to advance CD3 bispecifics against oncology targets nominated by AbbVie.

Key Points: 
  • Scripps and AbbVie will also work together in parallel to advance CD3 bispecifics against oncology targets nominated by AbbVie.
  • Under the terms of the license agreement, Scripps Research will continue to conduct pre-clinical research and development activities and, in some cases, Phase 1 clinical trials with AbbVie having an exclusive option to further develop and commercialize.
  • Scientists in the institute's five academic research departments work hand-in-hand with researchers of the Scripps Research Translational Institute and Calibr.
  • For more information about Calibr and Scripps Research visit www.calibr.org and www.scripps.edu .Follow @ScrippsResearch on Twitter, Facebook or LinkedIn .

Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)

Retrieved on: 
Wednesday, December 4, 2019
Chemical compounds, Organic compounds, RTT, Breakthrough therapy, Chloroarenes, Genentech, Sulfonamides, Venetoclax, Leukemia, AbbVie Inc.

The data show that onvansertib, as a single agent, inhibits tumor growth in venetoclax (Venclexta- Abbvie) resistant in-vitro and in-vivo models.

Key Points: 
  • The data show that onvansertib, as a single agent, inhibits tumor growth in venetoclax (Venclexta- Abbvie) resistant in-vitro and in-vivo models.
  • Additionally, the data also demonstrate synergy with the combination of onvansertib and venetoclax, providing further support for the ability of onvansertib to rescue patients once they show signs of resistance to venetoclax.
  • "We are very encouraged by the data suggesting that onvansertib will be able to rescue AML patients once they develop resistance to frontline treatment with venetoclax," said Dr. Mark Erlander, Chief Scientific Officer of Trovagene.
  • AML is the most common acute leukemia in adults and is most frequently diagnosed in those 65 to 74 years of age.

Inventiva receives a €3.5 m milestone payment from AbbVie

Retrieved on: 
Tuesday, December 3, 2019
AbbVie Inc., Companies, Euronext, Illinois

Frdric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: This new milestone is excellent news for Inventiva, especially as we have reached it much earlier than anticipated.

Key Points: 
  • Frdric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: This new milestone is excellent news for Inventiva, especially as we have reached it much earlier than anticipated.
  • In 2012, Inventiva and AbbVie signed a multi-year drug discovery collaboration to identify potent ROR inverse agonists for the treatment of several auto-immune diseases.
  • The collaboration between Inventiva and AbbVie entitles the Company to receive further milestone payments and royalties on future sales of ABBV-157.
  • Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA ISIN: FR0013233012).

Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone

Retrieved on: 
Tuesday, December 3, 2019
Science, Seniors, Biotechnology, Research, Pharmaceutical, Health, Consumer, Clinical trials, AbbVie Inc., Health, Companies, Parkinson's disease, Medicine

This is the first major milestone of the Companies DUB research and preclinical development collaboration in neurodegenerative diseases.

Key Points: 
  • This is the first major milestone of the Companies DUB research and preclinical development collaboration in neurodegenerative diseases.
  • Under the terms of the collaboration, announced in November 2018 , Mission and AbbVie are working together to identify specific DUBs and discover suitable inhibitor compounds for the treatment of Alzheimers and Parkinsons diseases.
  • Mission is eligible to receive success-based milestone payments and royalty payments for each commercialized product.
  • We look forward to continuing to work together to discover and develop DUB inhibitors towards the treatment of Alzheimers and Parkinsons diseases.

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue

Retrieved on: 
Wednesday, November 27, 2019
Financial markets, Stock market, Finance, Financial economics, Corporate finance, AbbVie Inc., Security, Stock exchange, Stock, New York Stock Exchange

AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.

Key Points: 
  • AbbVie's common stock is traded on the NYSE and Chicago Stock Exchange under the symbol ABBV.
  • The International Securities Identification Number (ISIN) of the AbbVie common stock is US00287Y1091.
  • Upon vesting, each Restricted Stock Unit and Performance Share entitles the holder to receive one share of common stock.
  • Any holder of 1% or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

Retrieved on: 
Thursday, November 21, 2019
Biotechnology, General Health, Pharmaceutical, Health, Infectious diseases, Companies, Drugs, Infectious causes of cancer, Combination drugs, Hepatitis C, Glecaprevir/pibrentasvir, AbbVie Inc., Hepacivirus C, BlackBerry Limited

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2019.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2019.
  • Fiscal Fourth Quarter and Year Ended September 30, 2019 Financial Results
    Total revenue of $51.3 million for the three months ended September 30, 2019 consisted of royalty revenue derived primarily from worldwide net sales of AbbVies hepatitis C virus (HCV) regimen MAVYRET/MAVIRET.
  • The decrease in royalty revenue quarter over quarter was driven by lower HCV product sales as reported by AbbVie.
  • Enanta plans to issue its fiscal first quarter 2020 financial results press release, and hold a conference call regarding those results, on February 6, 2020.

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

Retrieved on: 
Thursday, November 21, 2019
Weapons, Guided missiles, Harpoon, AbbVie Inc.

These agreements build upon the discovery collaboration established by the two companies in October 2017 and are expected to advance and broaden the use of Harpoons proprietary TriTAC platform.

Key Points: 
  • These agreements build upon the discovery collaboration established by the two companies in October 2017 and are expected to advance and broaden the use of Harpoons proprietary TriTAC platform.
  • In addition, we look forward to expanding our discovery collaboration to include up to six additional molecular targets.
  • Our collaboration with Harpoon has been productive and we look forward to further strengthening this collaboration.
  • Under the terms of the license and option agreement, Harpoon granted to AbbVie an option to license worldwide exclusive rights to HPN217.

California Life Sciences Association (CLSA) Adds Leaders from AbbVie, Merck and Lasana Partners to Board of Directors

Retrieved on: 
Wednesday, November 20, 2019
Health, Medical devices, General Health, Research, Science, Pharmaceutical, Biotechnology, Companies, California Healthcare Institute, CLSA, Californias, AbbVie Inc., Merck & Co., Economy of the United States, Health, Mohit Trikha, Ph.D., Vice President, Head of Oncology Early Development & AbbVie Bay Area Site Head, Lesley Stolz, Ph.D., Managing Director, Lasana Partners, Grace Han McMahon, Head of Transactions, Pacific Innovation Hub, Business Development & Licensing, Merck Research Laboratories, California Life Sciences Association (CLSA)

California Life Sciences Association (CLSA), the trade association representing Californias life sciences sector, today announced the expansion of its board of directors , adding three new members.

Key Points: 
  • California Life Sciences Association (CLSA), the trade association representing Californias life sciences sector, today announced the expansion of its board of directors , adding three new members.
  • Joining the board are:
    Im pleased to welcome Mohit Trikha of AbbVie, Lesley Stolz of Lasana Partners and Grace Han McMahon of Merck Research Laboratories to the board of California Life Sciences Association (CLSA).
  • California Life Sciences Association (CLSA) is the states largest and most influential life sciences advocacy and business leadership organization.
  • CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged.